GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement
RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene therapy for hemophilia. GeneVentiv plans to move the therapy into the clinic mid-2022. The technology, designated as GENV HEM offers a cure for all types of hemophilia patients with or without inhibitors to their missing clotting factors.
“There are promising gene therapies in development for hemophilia patients without inhibitors, but patients with inhibitors were being left behind. We’re changing that with a gene therapy for all hemophilia patients with or without inhibitors.”, said Damon Race, President and CEO of GeneVentiv Therapeutics.
About GeneVentiv Therapeutics
GeneVentiv Therapeutics is a preclinical gene therapy company focused on identifying, in-licensing, and developing transformative genetic medicines for diseases with significant unmet needs. GeneVentiv is advancing two first-in-class programs. GENV-HEM is a liver-directed gene therapy designed to provide activated Factor V (FVa) for patients with hemophilia A, with or without FVIII inhibitors. GENV-002 is an in vivo gene-editing therapy for both infantile-onset (IOPD) and late-onset (LOPD) Pompe disease, designed to stably integrate a functional GAA transgene and establish the liver as a durable source of GAA enzyme.
Together, these programs are designed to address serious diseases where significant unmet needs remain.
Explore, learn more and grow with us.
← Back to Media